Exosome-mediated Crosstalk Between Tumor Cells and Innate Immune Cells: Implications for Cancer Progression and Therapeutic Strategies
Overview
Authors
Affiliations
The increasing number of cancer-associated deaths despite the substantial improvement in diagnosis and treatment has sparked discussions on the need for novel biomarkers and therapeutic strategies for cancer. Exosomes have become crucial players in tumor development and progression, largely due to the diverse nature of their cargo content released to recipient cells. Importantly, exosome-mediated crosstalk between tumor and stromal cells is essential in reprogramming the tumor microenvironment to facilitate tumor progression. As a result, exosomes have gradually become a marker for the early diagnosis of many diseases and an important tool in drug delivery systems. However, the precise mechanisms by which exosomes participate in tumor progression remain elusive, multifaceted, and a double-edged sword, thus requiring further clarification. The available evidence suggests that exosomes can facilitate communication between innate immune cells and tumor cells to either support or inhibit tumor progression. Herein, this review focused on exosome-mediated intercellular communication between tumor cells and macrophages, neutrophils, mast cells, monocytes, dendritic cells, and natural killer cells. Specifically, how such intercellular communication affects tumor progression has been described. It has also been discussed that, depending on their cargo, exosomes can suppress or promote tumor cell progression. In addition, the potential application of exosomes and strategies to target exosomes in cancer treatment has been comprehensively discussed.
Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.
Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).
PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.
CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.
Kwantwi L, Boafo J, Egleh B, Li M Clin Transl Oncol. 2025; .
PMID: 39985603 DOI: 10.1007/s12094-025-03874-5.
Exosomal PDL1 Suppresses the Anticancer Activity of CD8 T Cells in Hepatocellular Carcinoma.
Hu Q, Chen S, Deng R, Deng H, Peng M, Wang X Anal Cell Pathol (Amst). 2024; 2024:1608582.
PMID: 39421264 PMC: 11483647. DOI: 10.1155/2024/1608582.
The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma.
Kwantwi L, Rosen S, Querfeld C Cancers (Basel). 2024; 16(19).
PMID: 39409988 PMC: 11482616. DOI: 10.3390/cancers16193368.
Kwantwi L, Tandoh T Clin Transl Oncol. 2024; .
PMID: 39269597 DOI: 10.1007/s12094-024-03723-x.